Upcoming Lecture

 

The Perry & Ruby Stevens Parkinson's Disease
Center of Excellence Virtual Seminar Series
 
presents
 
"LRRK2 neurobiology and Parkinson’s disease pathogenesis"
 
 

Wanli W. Smith, MD, PhD
Associate Professor
Director of Cellular Neurobiology Laboratory
Neurobiology Division, Department of Psychiatry
Johns Hopkins University School of Medicine
 
 
Friday, May 21, 2021
4:00 PM - 5:00 PM CST

 

CONNECT TO THIS VIRTUAL SEMINAR THROUGH MICROSOFT TEAMS:
 
Join on your computer or mobile app
Or call in (audio only)
+1 210-469-0159,,176741967#   United States, San Antonio
Phone Conference ID: 176 741 967#

 

 

 
 
 
The Parkinson's Disease Center of Excellence Lecture Series Planning Committee Members Robert Clark MD, Andrea Giuffrida PhD, and Randy Strong PhD have no relevant financial relationships with commercial interests to disclose.  Dr. Wanli Smith has no relevant financial relationships with commercial interests to disclose. 
 
 
The UT Health Long San Antonio School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 
The Long School of Medicine designates this live activity up to a maximum of 1.00 AMA PRA Category 1 CreditsTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

About Parkinson's Center of Excellence Seminar Series

The Parkinson's Center of Excellence Seminar Series is a collaborative project among: 

         

This monthly seminar series focuses on emerging advances in Parkinson's disease (PD), including both basic and translational research, novel treatment strategies, patient/caregiver issues, and community engagement/education.  Seminars will be presented by regional and national experts in PD pathogenesis and management, with an emphasis on evidence-based innovations in therapy.  Educational objectives will be defined to best meet the needs of participants, including physician providers, clinical researchers, nurses, therapists, patient advocacy groups, and other PD stakeholders.